资料单张
INDICATIONS [/za_1169.html#1]
[/za_1169.html#1] [/za_1169.html#1]
CONTRA-INDICATIONS [/za_1169.html#1]
[/za_1169.html#1]
DOSAGE [/za_1169.html#1]
[/za_1169.html#1]
SIDE-EFFECTS [/za_1169.html#1]
[/za_1169.html#1] [/za_1169.html#1]
PREGNANCY [/za_1169.html#1]
[/za_1169.html#1]
OVERDOSE [/za_1169.html#1]
IDENTIFICATION [/za_1169.html#1]
[/za_1169.html#1] PATIENT INFORMATION
GLYCOMIN™ TABLETS
SCHEDULING STATUS:
S3
PROPRIETARY NAME
(and dosage form):
GLYCOMIN™ TABLETS
COMPOSITION:
Tablets containing 5 mg
GLIBENCLAMIDE
.
PHARMACOLOGICAL CLASSIFICATION:
A 21.2 Oral hypoglycaemics.
PHARMACOLOGICAL ACTION:
Glycomin (glibenclamide) is a sulphonylurea which is an oral hypoglycaemic agent. Sulphonylureas stimulate the
pancreatic islet tissue to secrete insulin by causing degranulation of the ß-cells.
INDICATIONS:
Glycomin (glibenclamide) is used as an adjunct in the treatment of maturity-onset diabetics for whom dietary
management alone has been insufficient and insulin cannot be used.
CONTRA-INDICATIONS:
Hypersensitivity to sulphonylureas.
Insulin-dependent diabetics.
Diabetes in young people.
Glycomin (glibenclamide) is contra-indicated in diabetes mellitus complicated by ketoacidosis and in those with severe
infection, stress, trauma and severe impairment of renal, hepatic or thyroid function.
The safety of Glycomin (glibenclamide) in pregnancy is not established.
Chronic liver disease including that caused by uncompensated cardiac failure or alcoholism.
WARNING:
The administration of Glycomin (glibenclamide) may be associated with increased cardiovascular mortality compared
to treatment with diet alone or diet plus insulin.
DOSAGE AND DIRECTIONS FOR USE:
The usual initial dose is 5 mg daily, with or immediately before breakfast, adjusted after about 7 days by amounts of
2,5 mg daily
阅读完整的文件
资料单张 